[go: up one dir, main page]

NO20091501L - Farmasoytiske sammensetninger - Google Patents

Farmasoytiske sammensetninger

Info

Publication number
NO20091501L
NO20091501L NO20091501A NO20091501A NO20091501L NO 20091501 L NO20091501 L NO 20091501L NO 20091501 A NO20091501 A NO 20091501A NO 20091501 A NO20091501 A NO 20091501A NO 20091501 L NO20091501 L NO 20091501L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
granules
salt
prepared
pharmaceutically acceptable
Prior art date
Application number
NO20091501A
Other languages
English (en)
Other versions
NO346639B1 (no
Inventor
Nathalie Bruneau
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37684496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091501(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20091501L publication Critical patent/NO20091501L/no
Publication of NO346639B1 publication Critical patent/NO346639B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Det beskrives et farmasøytisk preparat, særlig kapsler, omfattende granuler inneholdende nilotinib eller et salt derav med minst en farmasøytisk akseptabel eksipient. Granulene kan fremstilles ved en våtgranuleirngsprosess.
NO20091501A 2006-09-27 2007-09-25 Farmasøytiske preparater og fremgangsmåte for fremstilling derav NO346639B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06121371A EP1923053A1 (en) 2006-09-27 2006-09-27 Pharmaceutical compositions comprising nilotinib or its salt
PCT/EP2007/060165 WO2008037716A2 (en) 2006-09-27 2007-09-25 Pharmaceutical compositions comprising nilotinib or its salt

Publications (2)

Publication Number Publication Date
NO20091501L true NO20091501L (no) 2009-04-24
NO346639B1 NO346639B1 (no) 2022-11-07

Family

ID=37684496

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20220946A NO347404B1 (no) 2006-09-27 2007-09-25 Granuler eller granulert blanding, samt farmasøytiske preparater omfattende slike
NO20091501A NO346639B1 (no) 2006-09-27 2007-09-25 Farmasøytiske preparater og fremgangsmåte for fremstilling derav

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20220946A NO347404B1 (no) 2006-09-27 2007-09-25 Granuler eller granulert blanding, samt farmasøytiske preparater omfattende slike

Country Status (34)

Country Link
US (2) US8293756B2 (no)
EP (4) EP1923053A1 (no)
JP (2) JP5567340B2 (no)
KR (2) KR20090076931A (no)
CN (2) CN101516344A (no)
AR (1) AR062980A1 (no)
AU (1) AU2007301977B2 (no)
BR (1) BRPI0719438B1 (no)
CA (1) CA2662571C (no)
CL (1) CL2007002766A1 (no)
CO (1) CO6160288A2 (no)
CY (2) CY1117021T1 (no)
DK (2) DK2068839T3 (no)
ES (3) ES2556625T5 (no)
FI (2) FI3984528T3 (no)
HR (2) HRP20151383T4 (no)
HU (2) HUE063083T2 (no)
IL (1) IL197496A (no)
JO (1) JO3757B1 (no)
LT (1) LT3984528T (no)
MA (1) MA30807B1 (no)
MX (1) MX2009003184A (no)
MY (1) MY148237A (no)
NO (2) NO347404B1 (no)
NZ (1) NZ575317A (no)
PE (2) PE20120626A1 (no)
PL (2) PL3984528T3 (no)
PT (2) PT3984528T (no)
RU (1) RU2469707C2 (no)
SI (2) SI3984528T1 (no)
TN (1) TN2009000093A1 (no)
TW (3) TWI540128B (no)
WO (1) WO2008037716A2 (no)
ZA (1) ZA200901511B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
EP2482820A2 (en) 2009-09-28 2012-08-08 Medizinische Universität Wien New use of pdgfrbeta inhibitors
MX2012004709A (es) * 2009-10-23 2012-05-23 Novartis Ag Metodo para el tratamiento de transtornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r.
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
WO2012164578A1 (en) * 2011-06-02 2012-12-06 Hetero Research Foundation Compositions and methods for preparing immediate release formulations of nilotinib
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
CN102321073A (zh) * 2011-08-12 2012-01-18 西安交通大学 一种尼罗替尼的制备方法
PH12014500897A1 (en) 2011-10-28 2019-10-07 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
AR088844A1 (es) * 2011-11-14 2014-07-10 Novartis Ag Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida
US9301957B2 (en) 2011-11-14 2016-04-05 Novartis Ag Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation
BR112015000349A2 (pt) 2012-07-11 2017-06-27 Novartis Ag método de tratamento de tumores estromais gastrointestinais
US9682081B2 (en) 2013-04-25 2017-06-20 Sun Pharmaceutical Industries Limited Pharmaceutical gastro-retentive solid oral dosage form of nilotinib
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
HRP20220358T1 (hr) 2014-08-11 2022-05-13 Sun Pharmaceutical Industries Limited Nove soli nilotiniba i njihovi polimorfi
WO2016033304A1 (en) * 2014-08-28 2016-03-03 Codexis, Inc. Imidazoyl anilide derivatives and methods of use
ES2935158T3 (es) * 2016-03-17 2023-03-02 Sun Pharmaceutical Ind Ltd Composición farmacéutica de nilotinib
CN107582531B (zh) * 2016-07-06 2020-12-29 四川科伦药物研究院有限公司 一种利伐沙班固体制剂及其制备方法
CN107320460B (zh) * 2017-08-04 2020-11-03 北京化工大学 一种尼罗替尼口服纳米制剂及其制备方法
CN107441094B (zh) * 2017-08-08 2020-05-22 南方医科大学 尼罗替尼作为治疗登革病毒感染的药物及其制药用途
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
CN112423757A (zh) 2018-06-15 2021-02-26 汉达生技医药责任有限公司 激酶抑制剂的盐类及其组合物
CA3168680A1 (en) * 2020-01-31 2021-08-05 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
EP4142699A1 (en) 2020-04-30 2023-03-08 Nanocopoeia LLC Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
JP7489849B2 (ja) * 2020-07-20 2024-05-24 日本化薬株式会社 ニロチニブ錠剤
JP2023543815A (ja) 2020-09-29 2023-10-18 シェンチェン ファーマシン シーオー．，エルティーディー． 医薬組成物
CA3224750A1 (en) 2021-06-19 2022-12-22 Helm Ag Granulate composition comprising nilotinib
WO2023285981A1 (en) * 2021-07-15 2023-01-19 Torrent Pharmaceuticals Limited Stable pharmaceutical liquid composition of nilotinib
EP4122452A1 (en) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
EP4642435A1 (en) 2022-12-29 2025-11-05 Renata Pharmaceuticals (Ireland) Limited Pharmaceutical suspension of nilotinib
WO2024194718A1 (en) * 2023-03-22 2024-09-26 Unichem Laboratories Limited A stable pharmaceutical composition and process for preparing thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072535A (en) * 1970-12-28 1978-02-07 A. E. Staley Manufacturing Company Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP3125221B2 (ja) * 1990-09-01 2001-01-15 大正製薬株式会社 ソファルコン含有固形製剤
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
CA2560523C (en) 1996-07-24 2011-09-20 Celgene Corporation Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing tnf.alpha. levels
TW426516B (en) * 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
FR2783421B1 (fr) * 1998-09-17 2000-11-24 Cll Pharma Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
DK1200090T3 (da) 1999-08-03 2013-11-25 Icos Corp Farmaceutisk formulering omfattende en beta-carbolin og dens anvendelse til behandling af seksuel dysfunktion
HRP20010582A2 (en) * 1999-12-08 2002-08-31 Pharmacia Corp Valdecoxib compositions
NZ519984A (en) 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US20060257482A1 (en) * 2002-06-07 2006-11-16 Patrik Kumar Modified release, multiple unit drug delivery systems
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AU2003288182A1 (en) * 2002-11-26 2004-06-18 Universiteit Gent Process and apparatus for continuous wet granulation of power material
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
WO2005011635A2 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
TR200301553A1 (tr) 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
WO2005065653A1 (en) * 2003-12-19 2005-07-21 E.I. Du Pont De Nemours And Company Intimate coating of ibuprofen with poloxamers to enhance aqueous dissolution
EP1776102A1 (en) 2004-07-28 2007-04-25 Ranbaxy Laboratories Limited Preparations of stable pharmaceutical compositions of nateglinide and processes for their preparation
CN101031285A (zh) * 2004-10-01 2007-09-05 卫材R&D管理有限公司 含有微粒的组合物及其制备方法
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
MX2007009135A (es) * 2005-01-28 2007-09-06 Novartis Ag Uso de pirimidilaminobenzamidas para el tratamiento de enfermedades que responden a la modulacion de la actividad de la cinasa tie-2.
RU2007135284A (ru) * 2005-02-25 2009-03-27 Новартис АГ (CH) Фармацевтические комбинации ингибиторов киназ bcr-abl и raf
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
RU2454220C2 (ru) * 2006-08-16 2012-06-27 Новартис Аг Способ получения твердых дисперсий высококристаллических терапевтических соединений
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt

Also Published As

Publication number Publication date
ES2951547T3 (es) 2023-10-23
CO6160288A2 (es) 2010-05-20
HK1133193A1 (en) 2010-03-19
JP5567340B2 (ja) 2014-08-06
IL197496A (en) 2016-04-21
NO346639B1 (no) 2022-11-07
RU2009115782A (ru) 2010-11-10
IL197496A0 (en) 2009-12-24
PL2068839T5 (pl) 2023-01-30
US20100087463A1 (en) 2010-04-08
US8293756B2 (en) 2012-10-23
KR20090076931A (ko) 2009-07-13
EP3009128B1 (en) 2023-07-05
PT2068839E (pt) 2015-12-30
CY1126116T1 (el) 2023-11-15
KR20140121903A (ko) 2014-10-16
ES2556625T3 (es) 2016-01-19
CA2662571A1 (en) 2008-04-03
FI3984528T3 (fi) 2023-07-27
EP3984528B1 (en) 2023-07-05
MY148237A (en) 2013-03-29
HUE028204T2 (en) 2016-12-28
PE20120626A1 (es) 2012-06-07
PE20081379A1 (es) 2008-11-27
SI3984528T1 (sl) 2023-09-29
AU2007301977B2 (en) 2011-09-08
EP1923053A1 (en) 2008-05-21
TWI428333B (zh) 2014-03-01
NO20220946A1 (no) 2009-04-24
TWI540128B (zh) 2016-07-01
DK2068839T3 (da) 2016-01-11
MX2009003184A (es) 2009-04-03
AR062980A1 (es) 2008-12-17
PL3984528T3 (pl) 2023-08-28
SI2068839T2 (sl) 2023-01-31
EP2068839B2 (en) 2022-10-12
AU2007301977A1 (en) 2008-04-03
TW201418244A (zh) 2014-05-16
WO2008037716A2 (en) 2008-04-03
US20130023549A1 (en) 2013-01-24
ES2556625T5 (es) 2023-03-02
HRP20230753T3 (hr) 2023-10-27
ES2957912T3 (es) 2024-01-29
ZA200901511B (en) 2010-02-24
EP2068839A2 (en) 2009-06-17
TW201418245A (zh) 2014-05-16
PL2068839T3 (pl) 2016-06-30
US8501760B2 (en) 2013-08-06
NO347404B1 (no) 2023-10-16
MA30807B1 (fr) 2009-10-01
CL2007002766A1 (es) 2008-08-08
FI2068839T4 (fi) 2023-01-31
WO2008037716A3 (en) 2008-07-17
HRP20151383T4 (hr) 2023-03-03
SI2068839T1 (sl) 2016-02-29
EP3009128A1 (en) 2016-04-20
BRPI0719438A2 (pt) 2013-12-10
DK3984528T3 (da) 2023-07-31
PT3984528T (pt) 2023-08-07
BRPI0719438B1 (pt) 2022-04-19
TW200821298A (en) 2008-05-16
RU2469707C2 (ru) 2012-12-20
JO3757B1 (ar) 2021-01-31
NZ575317A (en) 2011-12-22
EP2068839B1 (en) 2015-09-23
EP3984528A1 (en) 2022-04-20
JP2010504942A (ja) 2010-02-18
TN2009000093A1 (en) 2010-08-19
CN101516344A (zh) 2009-08-26
CA2662571C (en) 2016-09-27
LT3984528T (lt) 2023-08-10
CY1117021T1 (el) 2017-04-05
KR101598747B1 (ko) 2016-03-02
CN104306350A (zh) 2015-01-28
HUE063083T2 (hu) 2023-12-28
HRP20151383T1 (hr) 2016-01-15
JP2014065715A (ja) 2014-04-17

Similar Documents

Publication Publication Date Title
NO20091501L (no) Farmasoytiske sammensetninger
WO2010065709A3 (en) Hydroxamic acid derivatives, preparation and therapeutic uses thereof
PT2364983E (pt) Novo derivado tricíclico ou seus sais farmaceuticamente aceitáveis, seu método de preparação, e composição farmacêutica que o contém
CL2007003265A1 (es) Compuestos derivados de 1h-piran[2,3-d]pirimidin-2,4,7-triona; y composicion farmaceutica, util para el tratamiento de sindrome metabolico, dislipidemia y enfermedades cardiovasculares entre otras.
IL204052A (en) Annotation of 1,1,1 - Tripluoro - 2 - Hydroxy - 3 - Phenylpropane
CL2007003690A1 (es) Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.
BRPI0814666A2 (pt) composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
CL2007002376A1 (es) Compuestos derivados de pirrol sustituido; proceso de preparacion; composicion farmaceutica; y uso en enfermedades bacterianas.
WO2010056039A3 (en) Oral pharmaceutical formulation of pelubiprofen with improved dissolution rate and stability
DE502007005902D1 (de) -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
CL2007000680A1 (es) Compuesto cristalino (5s)-5-[4(cloro-piridin-2-iloxi)-piperidin-1-sulfonilmetil]-5-metil-imidazolidin-2,4-diona, forma g; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de epoc.
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
IL188069A0 (en) Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof
WO2009038412A3 (en) Beta-secretase inhibiting compounds
EP2551266A4 (en) 2',2-dithiazol non-nucleoside compounds, preparation methods, pharmaceutical compositions and uses as hepatitis virus inhibitors thereof
CL2008000982A1 (es) Compuestos derivados de 5-oxo-isoxazol-carboxamida; proceso de preparacion; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de
EP2497464A3 (en) Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture
FR2934780B1 (fr) Composition pharmaceutique sous forme de granules et procede de fabrication d'une telle composition pharmaceutique.
ATE479427T1 (de) Pharmazeutische zusammensetzung mit candesartan- cilexetil
PL1979321T3 (pl) Nowe pirydynyloaminoalkileno- i pirydynyloksyalkileno- cyklopropanoaminy, sposób ich wytwarzania i zawierające je kompozycje farmaceutyczne
WO2009087657A3 (en) Stable pharmaceutical composition of duloxetine and process for its preparation
AP2010005204A0 (en) New addition salts of angiotensinconverting enzymeir preparation and pharmaceutical compositions coninhibitors with no donor acids, a process for the taining them
WO2009121946A3 (en) Process for the preparation of optically enriched clopidogrel
ZA200902413B (en) Novel indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CL2007002807A1 (es) Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren